newsfilter
← Latest News
GlobeNewswire·

Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving